B3170
Monoclonal Anti-Bcl-2 antibody produced in mouse
clone Bcl-2-100, ascites fluid
别名:
Anti-BCL-2
登录 查看组织和合同定价。
选择尺寸
关于此项目
Conjugate:
unconjugated
Clone:
Bcl-2-100, monoclonal
Application:
ARR, EM, ICC, IHC (f), IHC (p), IP, WB
Citations:
41
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
Bcl-2-100, monoclonal
mol wt
antigen 26 kDa
contains
15 mM sodium azide
species reactivity
human
should not react with
mouse
technique(s)
electron microscopy: suitable, immunocytochemistry: suitable, immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable, immunohistochemistry (frozen sections): suitable, immunoprecipitation (IP): suitable, microarray: suitable, western blot: 1:1,000 using human HeLa cell extract
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BCL2(596)
正在寻找类似产品? 访问 产品对比指南
General description
BCL2 (B-cell lymphoma 2) consists of pro- and antiapoptotic functions. It belongs to BCL2 family of proteins. It is mapped to human chromosome 18q21.3.
Immunogen
synthetic peptide corresponding to residues 41-54 of the Bcl-2 protein, conjugated to thyroglobulin.
Application
Anti-BCL2 (Ab-56) antibody has been used in western blotting and immunocytochemistry.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Monoclonal Anti-Bcl-2 antibody produced in mouse is suitable for western blotting at a concentration of 1:1,000 by using human HeLa cell extract. It is also suitable for immunohistochemistry by using formalin-fixed, paraffin-embedded tissue sections or frozen sections. Further, the antibody may be used for the localization of Bcl-2, by implementing numerous assays like- microarray, electron microscopy and immunoprecipitation.
Biochem/physiol Actions
BCL2 (B-cell lymphoma 2) plays an important role in the growth and progression of cancer. Overexpression of BCL2 (B-cell lymphoma 2) results in poor clinical predictions in diffuse large B-cell lymphoma (DLBCL). Bcl2 is highly essential for the survival of kidney and melanocyte stem cells and mature lymphocytes. It may control Bcl2 multiple initiator caspases.
Protooncogene BCL2 encodes a 26 kD integral outer mitochondrial membrane protein expressed in sub-cellular components such as the mitochondria and nucleus. While mitochondrial BCL2 inhibits apoptosis, BCL2 present in the nucleus may activate cell death. It may also regulate autophagy during starvation. Additionally, BCL2 facilitates the survival of central and peripheral neurons grown in culture in the absence of neurotrophic factors.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
动植物来源生物产品
常规特殊物品
此项目有
The protein PprI provides protection against radiation injury in human and mouse cells
Shi Y, et al.
Scientific Reports (2016)
Raquel Vinhas et al.
Molecular therapy. Nucleic acids, 7, 408-416 (2017-06-19)
Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation
Tsuyama N, et al.
Blood, 130(4), 489-500 (2017)
Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway
Bao H, et al.
Oncology Letters, 14(3), 2831-2837 (2017)
BCL2 genotypes and prostate cancer survival
Renner W, et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [Et Al], 193(6), 466-471 (2017)
商品
Quantitative and qualitative western blotting to validate knockdown by esiRNA.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持